Search research articles
Contact Us
Filters
Showing results (1551-1560 of 1,873) with videos related to
Page
of 188
Sort By:
European Journal of Heart Failure
|
September 20, 2024
In-hospital course of patients with heart failure with improved ejection fraction in the DELIVER trial
Maria A Pabon, Muthiah Vaduganathan, Brian L Claggett, et al.
JACC. Heart Failure
|
February 5, 2025
EuroQol 5-Dimension Questionnaire in Heart Failure With Reduced, Mildly Reduced, and Preserved Ejection Fraction: A Patient-Level Analysis of DAPA-HF and DELIVER
Mingming Yang, Toru Kondo, Atefeh Talebi, et al.
JACC. Advances
|
November 28, 2024
Electronic Nudge Letters to Increase Influenza Vaccination Uptake in Younger and Middle-Aged Individuals With Diabetes
Mats C Højbjerg Lassen, Niklas Dyrby Johansen, Muthiah Vaduganathan, et al.
JACC. Heart Failure
|
September 2, 2025
Angiotensin-Neprilysin Inhibition and Left Ventricular Assist Device Therapy -Primary results of the multicENter, randomized, open-label, parallel group, study to evaluate the use of sacubitril/valsartan in HeartMate 3 LVAD recipients (ENVAD-HF)
Maja Cikes, Jasper J Brugts, Brian Claggett, et al.
European Heart Journal
|
June 8, 2022
Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial
Marco Metra, Matteo Pagnesi, Brian L Claggett, et al.
JACC. Heart Failure
|
August 12, 2019
Design of a "Lean" Case Report Form for Heart Failure Therapeutic Development
Mitchell A Psotka, Mona Fiuzat, Peter E Carson, et al.
The New England Journal of Medicine
|
November 3, 2009
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease
Marc A Pfeffer, Emmanuel A Burdmann, Chao-Yin Chen, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|
December 23, 2018
Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)
Finnian R Mc Causland, Brian Claggett, Emmanuel A Burdmann, et al.
JAMA Cardiology
|
May 22, 2023
Contemporary Use of Sodium-Glucose Cotransporter-2 Inhibitor Therapy Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction in the US: The Get With The Guidelines-Heart Failure Registry
Jacob B Pierce, Muthiah Vaduganathan, Gregg C Fonarow, et al.
Journal of Cardiac Failure
|
August 17, 2025
Growth differentiation factor-15 and the effect of dapagliflozin in heart failure: insights from the DAPA-HF trial
David D Berg, Kieran Docherty, Atefeh Talebi, et al.
Page
of 188
Search research articles
Search
Showing results (1551-1560 of 1,873) with videos related to
Sort By:
Page
of 188
European Journal of Heart Failure
|
September 20, 2024
In-hospital course of patients with heart failure with improved ejection fraction in the DELIVER trial
Maria A Pabon, Muthiah Vaduganathan, Brian L Claggett, et al.
JACC. Heart Failure
|
February 5, 2025
EuroQol 5-Dimension Questionnaire in Heart Failure With Reduced, Mildly Reduced, and Preserved Ejection Fraction: A Patient-Level Analysis of DAPA-HF and DELIVER
Mingming Yang, Toru Kondo, Atefeh Talebi, et al.
JACC. Advances
|
November 28, 2024
Electronic Nudge Letters to Increase Influenza Vaccination Uptake in Younger and Middle-Aged Individuals With Diabetes
Mats C Højbjerg Lassen, Niklas Dyrby Johansen, Muthiah Vaduganathan, et al.
JACC. Heart Failure
|
September 2, 2025
Angiotensin-Neprilysin Inhibition and Left Ventricular Assist Device Therapy -Primary results of the multicENter, randomized, open-label, parallel group, study to evaluate the use of sacubitril/valsartan in HeartMate 3 LVAD recipients (ENVAD-HF)
Maja Cikes, Jasper J Brugts, Brian Claggett, et al.
European Heart Journal
|
June 8, 2022
Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial
Marco Metra, Matteo Pagnesi, Brian L Claggett, et al.
JACC. Heart Failure
|
August 12, 2019
Design of a "Lean" Case Report Form for Heart Failure Therapeutic Development
Mitchell A Psotka, Mona Fiuzat, Peter E Carson, et al.
The New England Journal of Medicine
|
November 3, 2009
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease
Marc A Pfeffer, Emmanuel A Burdmann, Chao-Yin Chen, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|
December 23, 2018
Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)
Finnian R Mc Causland, Brian Claggett, Emmanuel A Burdmann, et al.
JAMA Cardiology
|
May 22, 2023
Contemporary Use of Sodium-Glucose Cotransporter-2 Inhibitor Therapy Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction in the US: The Get With The Guidelines-Heart Failure Registry
Jacob B Pierce, Muthiah Vaduganathan, Gregg C Fonarow, et al.
Journal of Cardiac Failure
|
August 17, 2025
Growth differentiation factor-15 and the effect of dapagliflozin in heart failure: insights from the DAPA-HF trial
David D Berg, Kieran Docherty, Atefeh Talebi, et al.
Page
of 188